dihydropyridines has been researched along with Brain-Damage--Chronic* in 2 studies
2 other study(ies) available for dihydropyridines and Brain-Damage--Chronic
Article | Year |
---|---|
Effect of a new calcium antagonist (SM-6586) on experimental cerebral ischemia.
SM-6586 (SM) is a new derivative of dihydropyridine with potent calcium blocking activity and inhibitory activity of the Na+/H+ and Na+/Ca++ exchange transport. The effect of SM on survival rate, brain edema and metabolites was evaluated using two different models in spontaneously hypertensive rat (SHR). Global ischemia was induced by bilateral common carotid artery ligation (BLCL) and focal ischemia was induced by middle cerebral artery occlusion. The survival rate after BLCL was higher in the SM-treated group. The brain water content was lower, the ATP level was higher and lactate level was lower in the SM-treated group compared to the control group. In focal ischemia models, the SM-treated group showed a reduction of T1 relaxation time. The brain water content was significantly decreased in the SM-treated group. These results indicate that SM was effective in ameliorating the ischemic insult in global and focal cerebral ischemia models. Topics: Animals; Blood-Brain Barrier; Brain Damage, Chronic; Brain Edema; Brain Ischemia; Calcium Channel Blockers; Dihydropyridines; Dose-Response Relationship, Drug; Energy Metabolism; Male; Oxadiazoles; Rats; Rats, Inbred SHR; Water-Electrolyte Balance | 1994 |
Prevention of stroke and brain damage with calcium antagonists in animals.
In a rat model of embolic stroke (permanent occlusion of the left middle cerebral artery [MCAO]), various 1,4-dihydropyridine calcium antagonists have been shown to attenuate brain damage and the resultant functional impairment when administered after MCAO. Dose-response curves reveal that isradipine is one of the most potent and efficacious representatives of this class of compounds, reducing the infarct size by more than 60%. These results suggest that isradipine, when administered shortly after stroke onset, may have beneficial effects in patients suffering from brain ischemia. When isradipine is used to normalize the high blood pressure in spontaneously hypertensive rats, it will, in addition, also protect the brain from damage engendered by a subsequent stroke. This is not the case if blood pressure is controlled with a calcium antagonist which does not cross the blood-brain barrier, suggesting that the brain protection seen with isradipine is not due to blood pressure normalization. Isradipine, when used as an antihypertensive, appears to have an additional beneficial effect within the brain itself. As high blood pressure is a major risk factor for stroke, such an additional benefit with isradipine would be particularly valuable in antihypertensive therapy. Topics: Animals; Antihypertensive Agents; Blood Pressure; Brain Damage, Chronic; Calcium Channel Blockers; Cerebrovascular Disorders; Dihydropyridines; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension; Isradipine; Male; Prognosis; Pyridines; Rats; Rats, Inbred SHR | 1991 |